Vertaling van "maintained a solid growth " (Nederlands → Frans) :

Tekturna/Rasilez (USD 103 million, +56% cc) maintained a solid growth rate driven by single-pill combinations Tekturna/Rasilez HCT and Valturna in the US.
Rasilez/Tekturna (USD 103 millions, +56% tcc) a conservé un taux de croissance élevé grâce aux associations de molécules dans un comprimé unique commercialisées sous les marques Rasilez/Tekturna HCT et Valturna aux Etats-Unis.

The US (USD 2.6 billion, +6% cc), as well as Latin America and Canada (USD 0.8 billion, +16% cc), maintained solid growth rates.
Tant les Etats-Unis (USD 2,6 milliards, +6% tcc) que l’Amérique latine et le Canada (USD 0,8 milliard, +16% tcc) ont conservé des taux de croissance solides.

Xolair (USD 218 million, +53% lc, Novartis sales), a biotechnology drug for moderate to severe persistent asthma in the US and severe persistent allergic asthma in Europe, has maintained solid growth based on approvals in more than 60 countries, including Japan since early 2009.
Xolair (USD 218 millions, +53% en m. l.), ventes de Novartis uniquement), médicament biotechnologique contre l’asthme persistant modéré à sévère aux Etats-Unis et contre l’asthme allergique persistant sévère en Europe, a continué de croître fortement à la suite de son autorisation dans plus de 60 pays, dont le Japon depuis début 2009.

The US (USD 7.5 billion, +6% cc) maintained solid growth rates, as did Latin America and Canada (USD 2.1 billion, +14% cc).
Les Etats-Unis (USD 7,5 milliards, +6% tcc) ont conservé des taux de croissance solides, de même que l’Amérique latine et le Canada (USD 2,1 milliards, +14% tcc).

The US (USD 2.6 billion, +7% cc), as well as Latin America and Canada (USD 0.7 billion, +15% cc), maintained solid growth rates.
Tant les Etats-Unis (USD 2,6 milliards, +7% tcc) que l’Amérique latine et le Canada (USD 0,7 milliard, +15% tcc) ont conservé des taux de croissance solides.

Latin America and Canada maintained solid growth rates (USD 0.6 billion, +12% cc).
L’Amérique latine et le Canada ont conservé de solides taux de croissance (USD 0,6 milliard, +12% tcc).

Exforge (USD 227 million, +37% cc) maintained solid growth in the second quarter fueled by continued geographic expansion and the launch of Exforge HCT, which adds a diuretic in a single pill, in the US and Europe.
Exforge (USD 227 millions, +37% tcc) a maintenu une croissance vigoureuse au deuxième trimestre, alimentée par une extension géographique continue et par le lancement aux Etats-Unis et en Europe d’Exforge HCT, qui ajoute un diurétique dans un seul comprimé.

31-okt-2013 Bayer continues positive business momentum Ongoing dynamic trend in Life Sciences; MaterialScience level with prior-year quarter / New pharmaceutical products post excellent growth / Group sales EUR 9,643 million (minus 0.2 percent; Fx & portfolio adj. plus 6.0 percent) / EBIT shows 47.5 percent improvement to EUR 1,221 million / EBITDA before special items moves 7.7 percent higher to EUR 1,984 million / Net income advances by 42.1 percent to EUR 733 million / Core earnings per share up 8.5 percent to EUR 1.27 / Group guidance for 2013 maintained » meer
31-oct.-2013 Bayer continues positive business momentum Ongoing dynamic trend in Life Sciences; MaterialScience level with prior-year quarter / New pharmaceutical products post excellent growth / Group sales EUR 9,643 million (minus 0.2 percent; Fx & portfolio adj. plus 6.0 percent) / EBIT shows 47.5 percent improvement to EUR 1,221 million / EBITDA before special items moves 7.7 percent higher to EUR 1,984 million / Net income advances by 42.1 percent to EUR 733 million / Core earnings per share up 8.5 percent to EUR 1.27 / Group guidance for 2013 maintained » En savoir plus